XRAY
HealthcareDENTSPLY SIRONA Inc. · Medical - Instruments & Supplies · $2B
What is DENTSPLY SIRONA Inc.?
DENTSPLY SIRONA is one of the world's largest manufacturers of dental products and technologies, serving professional dental markets across the globe. The company traces its roots to 1877 and is headquartered in Charlotte, North Carolina.
The company operates through two segments: Technologies & Equipment, and Consumables. The Technologies & Equipment segment covers dental treatment centers, imaging systems, CAD/CAM digital dentistry tools, clear aligner solutions under the SureSmile brand, implants, and handpieces. The Consumables segment supplies endodontic tools for root canal procedures, restorative materials such as dental ceramics and digital dentures, and everyday dental consumables including impression materials, whiteners, and sealants. Revenue is generated through sales to dental practitioners, specialists, and dental laboratories worldwide.
DENTSPLY SIRONA was founded in 1877 and is headquartered in Charlotte, North Carolina.
- Dental CAD/CAM systems for digital restorations
- SureSmile clear aligner solutions for orthodontics
- Dental imaging and treatment center equipment
- Endodontic tools and root canal consumables
- Restorative materials including ceramics and digital dentures
Is XRAY a Good Stock to Buy?
UQS Score rates XRAY as Below Average overall.
Among the five pillars, Valuation stands out as Attractive, suggesting the market may already be pricing in the company's challenges — which can be relevant context for value-oriented investors. The Growth and Risk pillars both register as Neutral, indicating neither a compelling expansion story nor an acute near-term danger signal.
Both the Quality and Moat pillars are rated Weak, pointing to structural concerns around business durability and the company's ability to defend its competitive position over time.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does XRAY pay dividends?
Yes — DENTSPLY SIRONA Inc. pays a dividend.
DENTSPLY SIRONA pays a regular dividend, which may appeal to income-oriented investors. Given the company's Below Average overall UQS Score and Weak Quality rating, investors should weigh dividend sustainability carefully. The dividend reflects a long-standing capital return policy, but the underlying business fundamentals warrant close monitoring before relying on it as a primary income source.
When does XRAY report earnings?
DENTSPLY SIRONA reports earnings on a quarterly cadence, typical for US-listed equities.
The company's Neutral Growth and Risk pillar ratings suggest results have been neither notably strong nor severely deteriorating in recent periods. Investors should track segment-level performance across Technologies & Equipment and Consumables for directional signals.
For the most recent quarter's results, visit DENTSPLY SIRONA's investor relations page directly.
XRAY Price History
-79.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in DENTSPLY SIRONA Inc.?
Based on DENTSPLY SIRONA Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
XRAY Long-term Outlook
With Growth rated Neutral, DENTSPLY SIRONA does not currently show the hallmarks of a high-velocity expansion story, but neither does it appear to be in sharp decline. The Attractive Valuation rating suggests the stock may reflect lowered expectations, which could limit downside if fundamentals stabilize. However, the Weak Quality and Moat ratings are meaningful headwinds — sustained improvement in profitability and competitive positioning would be needed to shift the overall UQS profile meaningfully upward.
Growth drivers
- Continued adoption of digital dentistry and CAD/CAM workflows
- Expansion of clear aligner and orthodontic product lines
- Recovery in global dental procedure volumes post-disruption
Key risks
- Weak competitive moat leaves market share vulnerable to rivals
- Quality pillar weakness signals potential pressure on margins or returns
- Valuation re-rating risk if growth fails to materialize
XRAY vs Peers
DENTSPLY SIRONA operates in the broader medical devices and healthcare products space alongside a range of specialized peers.
LeMaitre focuses narrowly on vascular surgery devices, giving it a more concentrated and specialized product portfolio than DENTSPLY SIRONA's broad dental platform.
Haemonetics specializes in blood management technologies, competing in a distinct clinical niche with different end-market dynamics than dental consumables and equipment.
Warby Parker addresses vision care through a direct-to-consumer eyewear model, representing a different approach to elective healthcare spending compared to DENTSPLY SIRONA's professional dental channel.
Frequently Asked Questions
What does DENTSPLY SIRONA do?
DENTSPLY SIRONA manufactures and sells dental products and technologies for professional dental markets worldwide. Its two segments cover dental equipment and CAD/CAM digital systems on one side, and consumable products like endodontic tools and restorative materials on the other. The company serves dentists, specialists, and dental laboratories globally.
Does XRAY pay dividends?
Yes, DENTSPLY SIRONA pays a regular dividend. Income-focused investors should review the company's investor relations page for the current dividend rate and payment schedule. Given the company's Weak Quality rating, assessing dividend sustainability alongside overall financial health is advisable.
When does XRAY report earnings?
DENTSPLY SIRONA reports earnings on a quarterly cadence, in line with standard practice for US-listed companies. For the exact schedule and most recent results, check the company's investor relations page.
Is XRAY a good stock to buy?
UQS Score rates XRAY as Below Average, driven by Weak Quality and Moat pillars. The Valuation pillar is Attractive, which may interest value-oriented investors, but structural concerns around business quality and competitive positioning are meaningful factors to weigh. The complete analysis is available to UQS Pro members.
Is XRAY overvalued?
Based on the UQS Valuation pillar, XRAY is currently rated Attractive, suggesting the stock is not considered overvalued relative to its fundamentals at this time. However, valuation alone does not make a complete investment case — quality and moat concerns remain relevant context.
How does XRAY compare to its competitors?
DENTSPLY SIRONA competes in the broader medical devices space alongside peers like LeMaitre Vascular, Haemonetics, and Warby Parker, though each operates in a distinct clinical or consumer niche. Full UQS Score comparisons across these peers are available to Pro members on each company's profile page.
What is XRAY's market cap bracket?
DENTSPLY SIRONA is classified as a mid-cap company. This places it in a segment of the market that typically offers more liquidity than small-caps while carrying different risk and growth dynamics than large-cap peers in the healthcare sector.
Who founded DENTSPLY SIRONA?
DENTSPLY SIRONA's origins date to 1877, making it one of the oldest companies in the dental industry. The modern entity was formed through a merger of DENTSPLY International and Sirona Dental Systems. Detailed founding history is widely available through the company's official corporate resources.
Is XRAY a long-term quality investment?
As a long-term quality indicator, XRAY's Below Average UQS Score — anchored by Weak Quality and Moat ratings — raises questions about durable competitive advantage and consistent returns over time. The Neutral Risk and Growth ratings suggest stability without strong upward momentum. Pro members can view the full pillar breakdown for deeper context.
What is the main competitive advantage of DENTSPLY SIRONA?
DENTSPLY SIRONA's scale and breadth across both dental equipment and consumables give it broad market coverage. However, the UQS Moat pillar is currently rated Weak, indicating that its competitive advantages may not be as durable or defensible as those of higher-rated peers in the healthcare sector.
What sector does XRAY belong to?
XRAY belongs to the Healthcare sector, specifically within dental products and technologies. It serves professional dental markets globally through both capital equipment and recurring consumable product lines, giving it exposure to both one-time purchases and repeat-purchase revenue streams.
Is XRAY a growth stock or value stock?
Based on its UQS profile, XRAY leans toward value territory — the Valuation pillar is Attractive while the Growth pillar is only Neutral. This combination suggests the stock may be priced for modest expectations rather than high-growth outcomes, which is more consistent with a value-oriented framing.
Unlock Full XRAY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare XRAY against sector peers side by side
- ✓Screen for stocks with stronger Quality and Moat ratings
- ✓Get the full analyst-style breakdown in one place
Pro Analysis
XRAY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 44.4 | 31.4 | 25.0 | 43.9 | 49.9 | 93.4 | -0.1 |
| May 17, 2026 | 44.5 | 31.6 | 25.0 | 43.9 | 49.9 | 93.6 | +0.5 |
| May 7, 2026 | 44.0 | 30.9 | 25.0 | 43.9 | 49.5 | 92.3 | +0.1 |
| Apr 26, 2026 | 43.9 | 30.9 | 25.0 | 43.9 | 49.5 | 91.4 | +0.1 |
| Apr 19, 2026 | 43.8 | 30.9 | 25.0 | 43.9 | 49.5 | 90.6 | -0.1 |
| Apr 14, 2026 | 43.9 | 30.9 | 25.0 | 43.9 | 49.5 | 91.3 | 0.0 |
| Apr 12, 2026 | 43.9 | 30.9 | 25.0 | 43.9 | 49.5 | 91.6 | 0.0 |
| Apr 5, 2026 | 43.9 | 30.9 | 25.0 | 43.9 | 49.5 | 91.8 | 0.0 |
| Apr 2, 2026 | 43.9 | 30.9 | 25.0 | 43.9 | 49.5 | 91.4 | — |
XRAY — Pillar Breakdown
Quality
— 31.4/100 (25%)DENTSPLY SIRONA Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 43.9/100 (20%)DENTSPLY SIRONA Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 49.9/100 (15%)DENTSPLY SIRONA Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 93.4/100 (15%)DENTSPLY SIRONA Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 25/100 (25%)DENTSPLY SIRONA Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for XRAY.
Score Composition
Financial Data
More Stock Analysis
How is the XRAY UQS Score Calculated?
The UQS (Unified Quality Score) for DENTSPLY SIRONA Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses DENTSPLY SIRONA Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether DENTSPLY SIRONA Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.